News from mitsubishi tanabe pharma america, inc. A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Nov 15, 2019, 10:00 ET Mitsubishi Tanabe Pharma America to Receive Essey Commitment to Cures Award From the ALS Community for Extensive Efforts and Collaboration in ALS Research, Development and Education

Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced the company will receive a 2019 Essey Commitment to Cures Award for furthering research ...

Oct 24, 2019, 12:44 ET First Patient Enrolled In MTPA REFINE-ALS Biomarker Study

Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced the first patient has been enrolled in the REFINE-ALS clinical study, designed to...

Sep 26, 2019, 10:00 ET Mitsubishi Tanabe Pharma America Announces Appointment Of Gustavo A. Suarez Zambrano, M.D., As Vice President, Medical Affairs

Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced the appointment of Gustavo A. Suarez Zambrano, M.D., to the leadership team as Vice...

Sep 23, 2019, 10:29 ET Mitsubishi Tanabe Pharma Corporation Group Announces Presentation of Patient-Reported Results from Phase 2 ND0612 Study at International Congress of Parkinson's Disease and Movement Disorders

Mitsubishi Tanabe Pharma Corporation Group announced today the presentation of an analysis of secondary, patient-reported outcomes from a Phase 2...

Sep 20, 2019, 09:30 ET Mitsubishi Tanabe Pharma America To Present On ALS Clinical Programs At 2019 Muscle Study Group Annual Scientific Meeting

Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced three presentations on amyotrophic lateral sclerosis (ALS) at the 2019 Muscle Study...

Aug 28, 2019, 10:00 ET Phase 3 Clinical Trial Evaluating Continuous Subcutaneous Carbidopa/Levodopa (ND0612) Initiated In The United States For Parkinson's Disease With Motor Fluctuations

Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced the initiation of the Phase 3 BouNDless study investigating the efficacy, safety and...

Aug 08, 2019, 09:59 ET More Than 4,000 U.S. Patients With ALS Treated With RADICAVA® (edaravone) In Two Years Since Availability, Mitsubishi Tanabe Pharma America Reports

Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced that more than 4,000 people with amyotrophic lateral sclerosis (ALS) in the United...

Jul 23, 2019, 09:00 ET Mitsubishi Tanabe Pharma America Presents At 2019 National ALS Registry Annual Meeting In Atlanta

Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced the company will present an update on its REFINE-ALS biomarker study during the Centers ...

May 06, 2019, 09:00 ET MTPA Announces Nationwide Database Of ALS Infusion Services To Help Patients And Caregivers Identify Local Providers

Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced the availability of a new infusion care database within the ALS Care Locator platform...

May 03, 2019, 09:00 ET Oxford BioDynamics Joins ALS Biomarker Study Sponsored By Mitsubishi Tanabe Pharma America

Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced Oxford BioDynamics has joined the REFINE-ALS study, which was designed to identify and...

May 02, 2019, 09:00 ET Post-Hoc Analyses of RADICAVA® (edaravone) Studies Show Phase 3 Study Design Minimized ALS Heterogeneity to Improve Trial Efficiency

Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced results from a post-hoc analysis that showed how the RADICAVA® (edaravone) Phase 3...

Apr 11, 2019, 09:00 ET Mitsubishi Tanabe Pharma America to Highlight ALS Research Initiatives at 2019 MDA Clinical & Scientific Conference

Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced poster presentations of amyotrophic lateral sclerosis (ALS) research at the 2019...

Apr 04, 2019, 09:00 ET Mitsubishi Tanabe Pharma America Announces Names Of Teens And Young Adults Chosen For Inclusion In ALSO US™ Initiative

Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced the first teens and young adults selected to participate and receive mentoring through...

Mar 28, 2019, 09:00 ET Mitsubishi Tanabe Pharma America Announces Collaboration With Massachusetts General Hospital On ALS Biomarker Study

Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced a collaboration with the Massachusetts General Hospital (MGH) Neurological Clinical...

Mar 01, 2019, 09:00 ET Mitsubishi Tanabe Pharma America Appoints Sam Shum as Vice President of Operations and Strategy

Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced the promotion of Sam Shum to its executive leadership team as Vice President of...

Feb 06, 2019, 09:00 ET Mitsubishi Tanabe Pharma America Announces More Than 3,500 ALS Patients In The U.S. Have Been Treated With RADICAVA® (edaravone)

Mitsubishi Tanabe Pharma America, Inc. (MTPA) this week marks its third anniversary with the announcement that more than 3,500 people with...

Jan 31, 2019, 11:08 ET MTPA Launches National Online Directory Of ALS Specialists And Neurologists At Multidisciplinary Centers

Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced the launch of a national online database of healthcare providers (HCPs) who treat...

Dec 06, 2018, 08:58 ET Mitsubishi Tanabe Pharma America Announces Collaborative Study To Identify And Measure Biomarkers In People With ALS

Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced it will conduct a study to identify and measure specific biomarkers in people with...

Nov 28, 2018, 09:38 ET Mitsubishi Tanabe Pharma America To Showcase ALS Research At 29th International Symposium On ALS/MND In Glasgow

Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced presentations on amyotrophic lateral sclerosis (ALS) at the 29th International...

Nov 15, 2018, 07:30 ET Mitsubishi Tanabe Pharma Group Companies To Present New Data On Investigational Oral Formulation Of Edaravone For ALS At 29th International Symposium On ALS/MND

Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced that Mitsubishi Tanabe Pharma group companies will present pharmacokinetic (PK) data on ...

Nov 05, 2018, 12:33 ET Mitsubishi Tanabe Pharma America's ALSO US™ Initiative Begins Accepting Artistic Submissions From Teens Impacted By ALS

Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced it is now accepting submissions of original visual and written artistic content from...

Oct 04, 2018, 12:37 ET Mitsubishi Tanabe Pharma Canada Announces Canadian Authorization Of RADICAVA™ (edaravone) To Treat ALS

Mitsubishi Tanabe Pharma Canada, Inc. (MTP-CA) today announced that Health Canada has granted market authorization of RADICAVA™ (edaravone) as an...

Sep 24, 2018, 12:04 ET Mitsubishi Tanabe Pharma America Appoints Joseph Scalia as Vice President of Sales and Marketing

Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced the appointment of Joseph Scalia to its executive leadership team as Vice President of...

Jun 21, 2018, 12:45 ET Mitsubishi Tanabe Pharma America to Present Data on RADICAVA® (edaravone) at the European Network for the Cure of ALS (ENCALS) Annual Meeting

Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced it will present three abstracts on RADICAVA® (edaravone) in amyotrophic lateral...

Apr 18, 2018, 10:22 ET Mitsubishi Tanabe Pharma America and NeuroDerm Announce Parkinson's Disease Presentations at American Academy of Neurology Annual Meeting

Mitsubishi Tanabe Pharma America, Inc. (MTPA) and NeuroDerm Ltd. (NeuroDerm) today announced presentations on Parkinson's disease (PD) at the 70th...